AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, today announced that on September 29, 2008, it received a letter from The Nasdaq Stock Market (“Nasdaq”) indicating that during the preceding 30 consecutive trading days, the closing bid price of Introgen’s common stock has been below the $1.00 minimum bid price per share required for continued listing on the Nasdaq Global Market under Nasdaq Marketplace Rule 4450(a)(5). This letter has no immediate effect on the listing of Introgen’s common stock.
